Literature DB >> 20700067

Reduction in coronary and peripheral vasomotor function in patients with HIV after initiation of antiretroviral therapy: a longitudinal study with positron emission tomography and flow-mediated dilation.

Ulrik Sloth Kristoffersen1, Niels Wiinberg, Claus Leth Petersen, Jan Gerstoft, Henrik Gutte, Anne-Mette Lebech, Andreas Kjaer.   

Abstract

OBJECTIVES: The mechanisms underlying the increased cardiovascular risk in patients with HIV on antiretroviral therapy (ART) are not known. Our aim was to study the endothelial function of the coronary arteries by cardiac perfusion positron emission tomography (PET) in patients with HIV initiating ART. In addition, flow-mediated dilation (FMD) of the brachial artery was measured.
METHODS: Patients with HIV scheduled to initiate ART (n=12) were included. NH3 perfusion PET and FMD scans were performed both before and 5 weeks (24-67 days) after initiation of ART. Data were compared with paired t-tests and a P value of less than 0.05 was considered significant.
RESULTS: No changes were found in the pulse-pressure-corrected myocardial rest perfusion (1.22+/-0.07-1.09+/-0.05 ml/min/g tissue, NS) or cold pressor reserve (1.18+/-0.08-1.27+/-0.05, NS). However, the maximal myocardial perfusion decreased 31% from 2.50+/-0.25 to 1.73+/-0.15 ml/min/g tissue (P=0.009) and the myocardial perfusion reserve decreased 20% from 3.11+/-0.32 to 2.48+/-0.25 (P=0.042). FMD decreased from 8.68+/-1.70 to 4.58+/-0.93% (P=0.027). No change was observed in nitroglycerin-mediated dilation (12.8+/-1.0-14.4+/-1.4%, NS).
CONCLUSION: In patients with HIV initiating ART, signs of development of endothelial dysfunction assessed by coronary perfusion PET and FMD were found early after starting medication.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20700067     DOI: 10.1097/MNM.0b013e32833d82e6

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  9 in total

1.  A randomized, controlled trial of the effect of rilpivirine versus efavirenz on cardiovascular risk in healthy volunteers.

Authors:  Samir K Gupta; James E Slaven; Lisa M Kamendulis; Ziyue Liu
Journal:  J Antimicrob Chemother       Date:  2015-07-13       Impact factor: 5.790

2.  Should HIV-infected patients be screened for silent myocardial ischaemia using gated myocardial perfusion SPECT?

Authors:  Denis Mariano-Goulart; Jean-Marc Jacquet; Nicolas Molinari; Aurélie Bourdon; Meriem Benkiran; Mélanie Sainmont; Luc Cornillet; Jean-Christophe Macia; Jacques Reynes; Fayçal Ben Bouallègue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-14       Impact factor: 9.236

3.  Coronary artery endothelial dysfunction is present in HIV-positive individuals without significant coronary artery disease.

Authors:  Micaela Iantorno; Michael Schär; Sahar Soleimanifard; Todd T Brown; Richard Moore; Patricia Barditch-Crovo; Matthias Stuber; Shenghan Lai; Gary Gerstenblith; Robert G Weiss; Allison G Hays
Journal:  AIDS       Date:  2017-06-01       Impact factor: 4.177

4.  Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.

Authors:  Samir K Gupta; Deming Mi; Sharon M Moe; Michael P Dubé; Ziyue Liu
Journal:  J Acquir Immune Defic Syndr       Date:  2013-11-01       Impact factor: 3.731

Review 5.  Review: comparison of PET rubidium-82 with conventional SPECT myocardial perfusion imaging.

Authors:  Adam A Ghotbi; Andreas Kjaer; Philip Hasbak
Journal:  Clin Physiol Funct Imaging       Date:  2013-09-13       Impact factor: 2.273

6.  HIV infection and arterial inflammation assessed by (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET): a prospective cross-sectional study.

Authors:  Andreas Knudsen; Anne Mette Fisker Hag; Annika Loft; Eric von Benzon; Sune H Keller; Holger Jon Møller; Anne-Mette Lebech; Rasmus Sejersten Ripa; Andreas Kjær
Journal:  J Nucl Cardiol       Date:  2014-12-03       Impact factor: 5.952

7.  HIV infection, antiretroviral therapy, and measures of endothelial function, inflammation, metabolism, and oxidative stress.

Authors:  Andrew Dysangco; Ziyue Liu; James H Stein; Michael P Dubé; Samir K Gupta
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

8.  Coronary Microvascular Dysfunction in HIV: A Review.

Authors:  Leah Rethy; Matthew J Feinstein; Arjun Sinha; Chad Achenbach; Sanjiv J Shah
Journal:  J Am Heart Assoc       Date:  2019-12-19       Impact factor: 5.501

9.  Normal Myocardial Flow Reserve in HIV-Infected Patients on Stable Antiretroviral Therapy: A Cross-Sectional Study Using Rubidium-82 PET/CT.

Authors:  Andreas Knudsen; Thomas E Christensen; Adam Ali Ghotbi; Philip Hasbak; Anne-Mette Lebech; Andreas Kjær; Rasmus Sejersten Ripa
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.